Tracking a new Drug's journey through the body

NCT ID NCT06627231

Completed Knowledge-focused Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. Source: ClinicalTrials.gov ↗

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This early-stage trial aims to understand how the body absorbs, breaks down, and eliminates an experimental drug called TEV-56286 (emrusolmin). Eight healthy men will take the drug by mouth, including a version with a radioactive label that lets researchers trace its path. The study measures how much of the drug reaches the blood, how long it stays, and how it leaves the body. It also checks for any side effects. This is a first step in drug development, not a test of whether the drug treats a disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TEV-56286 (emrusolmin), given as an oral capsule, including a radiolabeled version to track its path through the body
What this could lead to: If successful, this trial will clarify how TEV-56286 is processed and cleared by the body, which is a key step toward developing it as a treatment.
What could go wrong: This is a very early, small study in healthy volunteers, not patients. It focuses on drug handling, not on whether the drug works for any disease, and results may not predict effects in patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY PARTICIPANTS

Contacts and locations

Locations

Teva Investigational Site 38189

Groningen, 9728 NZ, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.